Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human FLT1 Anticorps:
anti-Rat (Rattus) FLT1 Anticorps:
anti-Mouse (Murine) FLT1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Mouse (Murine) Polyclonal FLT1 Primary Antibody pour BR, ELISA (Capture) - ABIN5013029
Matsuno, Kozawa, Yoshimi, Akamatsu, Hara, Mori, Okada, Ueshima, Matsuo, Uematsu: Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. dans Blood 2002
Show all 25 Pubmed References
Human Polyclonal FLT1 Primary Antibody pour BR, CyTOF - ABIN5013028
Giuliani, Colla, Lazzaretti, Sala, Roti, Mancini, Bonomini, Lunghi, Hojden, Genestreti, Svaldi, Coser, Fattori, Sammarelli, Gazzola, Bataille, Almici, Caramatti, Mangoni, Rizzoli: Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. dans Blood 2003
Show all 23 Pubmed References
Human Monoclonal FLT1 Primary Antibody pour FACS - ABIN4897100
Karrar, Broomé, Uzunel, Qureshi, Sumitran-Holgersson: Human liver sinusoidal endothelial cells induce apoptosis in activated T cells: a role in tolerance induction. dans Gut 2007
Show all 18 Pubmed References
Human Monoclonal FLT1 Primary Antibody pour CyTOF, FACS - ABIN4900044
Brave, Eberlein, Shibuya, Wedge, Barry: Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. dans Angiogenesis 2010
Show all 8 Pubmed References
Human Monoclonal FLT1 Primary Antibody pour FACS - ABIN4897099
de Groot, Piao, Tran, Gilbert, Wu, Liu, Bekele, Cloughesy, Mehta, Robins, Lassman, DeAngelis, Camphausen, Chen, Yung, Prados, Wen, Heymach: Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. dans Clinical cancer research : an official journal of the American Association for Cancer Research 2011
Show all 6 Pubmed References
Mouse (Murine) Monoclonal FLT1 Primary Antibody pour FACS - ABIN4897107
Reddy, Zhou, Schadler, Jia, Kleinerman: Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. dans Molecular cancer research : MCR 2008
Show all 5 Pubmed References
Human Polyclonal FLT1 Primary Antibody pour ICC, IF - ABIN151960
Rahimi, Dayanir, Lashkari: Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. dans The Journal of biological chemistry 2000
Show all 5 Pubmed References
Mouse (Murine) Monoclonal FLT1 Primary Antibody pour FACS - ABIN4897104
Weston, Zayas, Perez, George, Jurecic: Dynamic equilibrium of heterogeneous and interconvertible multipotent hematopoietic cell subsets. dans Scientific reports 2014
Show all 3 Pubmed References
Human Polyclonal FLT1 Primary Antibody pour IF (p), IHC (p) - ABIN725795
Cheng, Xiang, Yang, Ma, Zhao: Direct Effects of Bevacizumab on Rat Conjunctival Fibroblast. dans Cell biochemistry and biophysics 2015
Show all 3 Pubmed References
Human Polyclonal FLT1 Primary Antibody pour WB - ABIN2801854
Kendall, Thomas: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. dans Proceedings of the National Academy of Sciences of the United States of America 1993
Show all 2 Pubmed References
This is the first report demonstrating the spatiotemporal expression patterns of Flk1 (Montrer KDR Anticorps) and Flt1 in the coronary vascular system during development and after MI; thus, this study suggests that these factors have distinct and important functions in coronary angiogenesis.
sFlt-1 overexpression in Padi4 (Montrer PADI4 Anticorps)(-/-) mice resulted in dramatically lower inflammatory and thrombotic response, which was accompanied by significant reduction in pregnancy losses. Inhibition of NETosis may serve as a novel target in disorders of impaired placentation.
endothelial dysfunction due to high circulating sFLT1 may be the primary event leading to enhanced vasoconstrictor sensitivity that is characteristic of preeclampsia
Flt1 has a role in blood vessel anastomosis during angiogenesis
First-in-class selective PET tracers for imaging VEGFR-1 and VEGFR-2 (Montrer KDR Anticorps) were constructed and successfully validated in an orthotopic murine tumor model.
these results suggest that VEGFR1 signaling plays a role in regulating the balance between macrophage phenotypes in streptozotocin -induced diabetic wounds, prevents impaired diabetic wound healing, and promotes angiogenesis/lymphangiogenesis.
These data therefore support a tightly controlled, paracrine signaling mechanism of VEGF-B (Montrer VEGFB Anticorps) to VEGFR1.
Flt1/VEGF-A (Montrer VEGFA Anticorps) signalling has stage-specific effects on vascular morphogenesis.
IL-35 treatment reduced collagen-induced arthritis via inhibiting vascular endothelial growth factor and its receptors
the VEGFR-1 tyrosine kinase (Montrer TYRO3 Anticorps) signaling has an effect on angiogenesis.
Icrucumab and ramucirumab are recombinant human IgG1 monoclonal antibodies that bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR-1 and -2), respectively. VEGFR-1 activation on endothelial and tumor cell surfaces increases tumor vascularization and growth and supports tumor growth via multiple mechanisms, including contributions to angiogenesis and direct promotion of cancer cell proliferation.
Cases with high MDSC infiltration, which was inversely correlated with intratumoral CD8(+) T-cell infiltration, exhibited shorter overall survival. In a mouse model, intratumoral MDSCs expressed both VEGFR1 and VEGFR2. VEGF expression in ovarian cancer induced MDSCs, inhibited local immunity, and contributed to poor prognosis
Circulating tissue transglutaminase is associated with sFlt-1, soluble endoglin and VEGF in the maternal circulation of preeclampsia patients, suggesting that tTG may have a role in the pathogenesis of PE.
The authors observed direct damage caused by sFLT1 in tumour cells. They exposed several kinds of cells derived from ovarian and colorectal cancers as well as HEK293T cells to sFLT1 in two ways, transfection and exogenous application. The cell morphology and an lactate dehydrogenase assay revealed cytotoxicity.
Altered antiangiogenic state because of altered circulating sFlt1 leads to Preeclampsia, ratio of sFlt1/PlGF (Montrer PGF Anticorps) correlates with Preeclampsia phenotypes.
Gestation-adjusted sEng, sFlt-1 and PlGF (Montrer PGF Anticorps) levels were 11%, 36%, and 30%, respectively, lower in women who later suffered miscarriage compared with unaffected pregnancies
the optimal discrimination cut-off for each cytokine: sVEGFR-1 (2124.5pg/mL), IL-6 (Montrer IL6 Anticorps) (40.2pg/mL), VEGF-A (Montrer VEGFA Anticorps) (1060.1pg/mL), Angiopoeintin-2 (913.7pg/mL), uPA (Montrer PRAP1 Anticorps) (248.1pg/mL), sHER-2/neu (Montrer ERBB2 Anticorps) (5010pg/mL) and PLGF (Montrer PGF Anticorps) (93.4pg/mL). For the very first time, a novel cytokine profile associated with cancer metastasis to the paratracheal lymph nodes were reported.
Results indicate that miR (Montrer MLXIP Anticorps)-507 represented potential therapeutic targets in breast cancer by modulating fms-related tyrosine kinase-1 (Flt-1).
VEGF (Montrer VEGFA Anticorps)-Flt-1 signaling induces osteoclastogenesis in OSCC through two possible ways: 1) VEGF (Montrer VEGFA Anticorps) produced from OSCC cells can directly stimulate the Flt-1 pathway in preosteoclasts to induce migration to future bone resorbing area and differentiation into osteoclasts, and 2) VEGF (Montrer VEGFA Anticorps)-Flt-1 signaling upregulates RANKL (Montrer TNFSF11 Anticorps) expression in OSCC cells, which indirectly leads to osteoclast differentiation
Study demonstrates that placental-specific overexpression of hsFlt-1 alters placental morphology and trophoblast differentiation and interferes with IGF2 and nutrient transporter expression leading to intrauterine growth restriction.
There is a possibility that steatosis can be suppressed by the CC genotype in VEGFR1.
These results suggest that non-dominant follicles maintain a greater concentration of the mRNA expression of both membrane and soluble VEGF receptors; but follicular dominance is related to a reduction in the mRNA expression of sVEGFR1 and sVEGFR2.
VEGFR-1 negatively regulates primary bovine retinal pericytes survival, and its blockade protects the blood-brain barrier integrity.
gamma-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1
VEGFR1 mRNA expression was lower at estrus and at the early I and early II luteal stages than at the other stages, whereas VEGFR1 protein expression did not change significantly throughout the estrous cycle (P<0.05)
Alterations in the expression of VEGF-A (Montrer VEGFA Anticorps) and bFGF (Montrer FGF2 Anticorps) systems suggest that angiogenic factors are involved in abnormal placental development in cloned gestations, contributing to impaired fetal development and poor survival rates.
inhibition of VEGFR-1 results in decrease in number of capillary connections indicating VEGFR-1 ligands promote branching angiogenesis.
TGF-beta1 (Montrer TGFB1 Anticorps) induction of VEGFR-1 in endothelial cells explains pericyte protection of vessels and the selective vulnerability of neonatal vessels to oxygen(VEGFR-1)
the activation of VEGFR-1 and VEGFR-2 (Montrer KDR Anticorps) heterodimer (VEGFR-1/R-2) is essential for PGI(2 (Montrer PTGIR Anticorps)) synthesis mediated by VEGF-A (Montrer VEGFA Anticorps)(165) and VEGF-A (Montrer VEGFA Anticorps)(121), which cannot be reproduced by the parallel activation of VEGFR-1 and VEGFR-2 (Montrer KDR Anticorps) homodimers with corresponding agonists
PEDF (Montrer SERPINF1 Anticorps) and VEGFR-1 have roles in the negative regulation of angiogenesis
we analyzed the expression and cellular distribution of Flt-1(VEGFR-1) and Flk-1 (KDR/VEGFR-2 (Montrer KDR Anticorps))in newborn piglet brain
data shows that members of the VEGF (Montrer VEGFA Anticorps)-VEGFR (Montrer KDR Anticorps) system are temporally and spatially well localized for playing key roles during umbilical cord formation and its intensive growth observed after day 75 of pregnancy
The VEGFR1 was stably expressed during the whole lifespan of mesonephric glomeruli, and VEGFR1 is important for the maintenance of endothelial fenestrations.
increased placental expression of the VEGF receptor system is associated with increased placental vascular density observed with the advancement of gestation in the pig.
EGFR (Montrer EGFR Anticorps), VEGFR (Montrer KDR Anticorps) and FGFR (Montrer FGFR2 Anticorps) are expressed in porcine oviduct and endometrium during the time of implantation [review]
VEGF ligand-receptor system may play an important role in the development and maintenance of the corpus luteum in pigs.
VEGF (Montrer VEGFA Anticorps)/Flk-1 (Montrer KDR Anticorps)/Flt-1 system is activated during myocardial ischemia reperfusion injury.
Hemodialysis graft placement leads to early increases in wall shear stress, VEGF-A (Montrer VEGFA Anticorps), pro-MMP-9 (Montrer MMP9 Anticorps), MMP-2 (Montrer MMP2 Anticorps), VEGFR-1, VEGFR-2 (Montrer KDR Anticorps), and TIMP-1 (Montrer TIMP1 Anticorps), which may contribute to the development of venous stenosis.
in experimental intervertebral disc degeneration, VEGF receptors were expressed in the damaged disc and paradiscal tissues
we determined that radial glia control this process via the Vegf (Montrer VEGFA Anticorps) decoy receptor sFlt1: sflt1 mutants exhibit the venous over-sprouting observed in radial glia-ablated larvae, and sFlt1 overexpression rescues it. Genetic mosaic analyses show that sFlt1 function in trunk endothelial cells can limit their over-sprouting.
Flt1-tyrosine kinase (TK) activity contributed significantly in endothelial cells survival and vascular development during embryo angiogenesis in zebrafish by engaging PI3K/Akt (Montrer AKT1 Anticorps) pathway.
Elevated Notch (Montrer NOTCH1 Anticorps) signaling downstream of perturbed VEGF (Montrer VEGFA Anticorps) signaling contributes to aberrant flt-1(-/-) blood vessel formation.
Data indicate that the increase in FLT1/sFLT1 protein levels upon miR-10 (Montrer LILRB2 Anticorps) knockdown inhibited the angiogenic behavior of endothelial cells largely by antagonizing vascular endothelial growth factor receptor 2 (Montrer KDR Anticorps) signaling.
This gene encodes a member of the vascular endothelial growth factor receptor (VEGFR) family. VEGFR family members are receptor tyrosine kinases (RTKs) which contain an extracellular ligand-binding region with seven immunoglobulin (Ig)-like domains, a transmembrane segment, and a tyrosine kinase (TK) domain within the cytoplasmic domain. This protein binds to VEGFR-A, VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis. Expression of this receptor is found in vascular endothelial cells, placental trophoblast cells and peripheral blood monocytes. Multiple transcript variants encoding different isoforms have been found for this gene. Isoforms include a full-length transmembrane receptor isoform and shortened, soluble isoforms. The soluble isoforms are associated with the onset of pre-eclampsia.
fms-like tyrosine kinase 1
, fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
, tyrosine-protein kinase FRT
, tyrosine-protein kinase receptor FLT
, vascular endothelial growth factor receptor 1
, vascular permeability factor receptor
, FMS-like tyrosine kinase 1
, Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
, vascular endothelial growth factor receptor-1
, fms-related tyrosine kinase 1
, receptor tyrosine kinase Flt1b
, soluble fms-like tyrosine kinase 1
, embryonic receptor kinase 2
, vascular endothelial growth factor/vascular permeability factor receptor
, ascular endothelial growth factor/vascular permeability factor receptor
, vascular endothelial growth factor 1
, flt-1 type VEGF receptor